ABG
PRAX icon

Ally Bridge Group’s Praxis Precision Medicines PRAX Stock Holding History

Ally Bridge Group’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-32,810
Closed -$10.6M – 32
2026
Q1 		$10.6M Buy
32,810
+12,928
+65% +$4M 8.54% 1
2025
Q4 		$5.86M Buy
+19,882
New +$3.7M 6.1% 9
2025
Q3 		– Sell
-80,880
Closed -$3.92M – 33
2025
Q2 		$3.4M Sell
80,880
-14,702
-15% -$560K 2.83% 18
2025
Q1 		$3.62M Buy
95,582
+50,600
+112% +$3.16M 3.26% 10
2024
Q4 		$3.46M Sell
44,982
-28,203
-39% -$2.04M 2.97% 14
2024
Q3 		$4.21M Sell
73,185
-80,194
-52% -$4.33M 2.25% 27
2024
Q2 		$6.34M Sell
153,379
-6,107
-4% -$289K 3.78% 13
2024
Q1 		$9.73M Buy
159,486
+89,062
+126% +$4M 5.41% 7
2023
Q4 		$1.57M Sell
70,424
-1
-0% -$18 0.93% 18
2023
Q3 		$1.81M Sell
70,425
-142,908
-67% -$2.7M 2.12% 15
2023
Q2 		$3.68M Buy
+213,333
New +$3.27M 4.46% 11
2023
Q1 		– Sell
-42,039
Closed -$1.5M – 32
2022
Q4 		$1.5M Buy
+42,039
New +$1.31M 1.46% 24

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Ally Bridge Group's PRAX Position: Q2 2026 in Review

Ally Bridge Group sold out of Praxis Precision Medicines (PRAX) in Q2 2026, closing a stake of 32,810 shares — an estimated $10.6M sold.

Ally Bridge Group first reported a position in PRAX in Q4 2022 and held it in 12 quarters. The position peaked at $10.6M in Q1 2026. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Ally Bridge Group reported no remaining Praxis Precision Medicines position as of Q2 2026 after selling out during the quarter.
  • Ally Bridge Group sold 32,810 Praxis Precision Medicines shares in Q2 2026, an estimated $10.6M.
  • Ally Bridge Group first reported a position in Praxis Precision Medicines in Q4 2022 and held it in 12 quarters.
  • Ally Bridge Group's Praxis Precision Medicines position peaked at $10.6M in Q1 2026.
  • 310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.